|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
Treatment of the symptoms of cognitive decline of ischemic origin in elderly patients. Treatment of the symptoms of neurosensory decline of ischemic origin in elderly patients, including visual and auditory deficit. Treatment of tinnitus, vertigo and balance disorders of ischemic origin in elderly patients. this Drug belong to the (diphenylmethyl) group
Avoid concurrent administration w/ MAOIs, almitrine.
Rare side effects have been reported: Weight loss, peripheral neuropathy with abnormal sensations in the lower limbs or paresthesiae (prickling, pins-and-needles, numbness). These effects have usually been observed during the long-term treatment of ≥1 year. These signs disappear following cessation of the treatment. Nausea, heartburns and epigastric heaviness, dyspepsia, disorders of the intestinal transit, sleep disorders eg, insomnia or drowsiness, agitation, anxiety, palpitations, vertiginous sensations.
Do not associate with the MAOIs.
In hypertensive patients, almitrine-raubasine does not replace specific antihypertensive treatment. Almitrine-raubasine should not be co-prescribed with other preparations containing almitrine (Vectarion). In hypertensive patients, almitrine-raubasine does not replace specific antihypertensive treatment. Almitrine-raubasine should not be co-prescribed with other preparations containing almitrine (Vectarion). Do not exceed the recommended dose. In case of persistent paresthesiae of the lower limbs or in case of body weight loss of >5%, it is recommended to stop the treatment. Use in pregnancy: The use of almitrine-raubasine is not recommended in women of childbearing age, especially during the first months of pregnancy, unless in the doctor’s opinion, the therapeutic benefit outweighs the possible risks.
SOLUTION FOR INJECTION
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Dr. Faisal Dibsi
Dr. Samer Al-Jneidy
Samir Moussa M.D.
Dr. Talal Sabouni
Yaser Habrawi , F.R.C.S.Ed
Dr. Hani Najjar
Dr. Tahsin Martini
Dr . Dirar Abboud